Evidence map›Paper›PMID 42687104›Full record

ArticleInternational journal of hematology2026

Baseline plasma EBV-DNA load as an adjunctive biomarker for refractory or recurrent disease in pediatric EBV-HLH.

Yu Furui, Rintaro Ono, Shohei Shigeto, Ryu Yanagisawa, Yozo Nakazawa, Kenichi Sakamoto

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu FuruiDepartment of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Rintaro OnoDepartment of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
Shohei ShigetoDepartment of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
Ryu YanagisawaDepartment of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Yozo NakazawaDepartment of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Kenichi SakamotoDepartment of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. sakamoto-k@shinshu-u.ac.jp.ORCID http://orcid.org/0000-0003-1499-538X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundQuantitative Epstein-Barr virus (EBV)-DNA measurement is used in EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH), but the optimal sample type for risk assessment and monitoring remains unclear.

methodsWe retrospectively analyzed 71 pediatric patients with newly diagnosed EBV-HLH from a Japanese multicenter cohort between April 2019 and May 2025. EBV-DNA loads in plasma, white blood cells, and T- and B-cell fractions were centrally quantified by real-time polymerase chain reaction. Patients were classified into remission and refractory/recurrent (R/R) groups.

resultsBaseline plasma EBV-DNA was higher in the R/R group than in the remission group (median, 5.762 vs. 5.366 log

conclusionsBaseline plasma EBV-DNA may serve as an adjunctive marker for disease assessment and monitoring in pediatric EBV-HLH, but not as a stand-alone predictor.

Indexed as

EB virus-associated hemophagocytic lymphohistiocytosisEpstein–Barr virusHemophagocytic lymphohistiocytosisPediatricPlasma EBV-DNA

Identifiers

PMID42687104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.